| 产品描述 | Lometrexol (DDATHF) disodium, an antipurineantifolate, can inhibit the activity ofglycinamide ribonucleotide formyltransferase (GARFT)but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo purine synthesis, causing abnormal cell proliferation andapoptosis, even cell cycle arrest. Lometrexol disodium has anticancer activity. Lometrexol disodium also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor[1][2][3]. Lometrexol (DDATHF) disodium binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides[3].
Lometrexol (1-30 μM; 2-10 hours) disodium induces rapid and complete growth inhibition in L1210 cells[3].
Lometrexol (1 μM; 2-24 hours) disodium induces cell cycle arrest in murine leukemia L1210 cells[3].
Cell Viability Assay[3] | Cell Line: | Mouse leukemia L1210 cells | | Concentration: | 1, 30 μM | | Incubation Time: | 2, 4, 6, 8, 10 hours | | Result: | Induced rapid and complete growth inhibition. |
Cell Cycle Analysis[3] | Cell Line: | L1210 cells | | Concentration: | 1 μM | | Incubation Time: | 2, 4, 8, 12, 24 hours | | Result: | Caused a rapid loss of the G2/M phase population of cells and an early S phase accumulation of cells by 8 hours. By 24 h, the S phase population appeared to be slowly shifting to higher DNA content, and hence, from mid-to-late S phase. |
Lometrexol (DDATHF; i.p.; 15-60 mg/kg; on gestation day 7.5) disodium induces neural tube defects (NTDs) by disturbing purine metabolism and increases the rate of embryonic resorption and growth retardation in a dose-dependent manner[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) disodium decreases glycinamide ribonucleotide formyl transferase (GARFT) activity and Changes of ATP, GTP, dATP and dGTP levels[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) disodium induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs)[1].
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 15, 30, 35, 40, 45 and 60 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5 | | Result: | Increased the rate of embryonic resorption and growth retardation in a dose-dependent manner. |
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5, for 0, 6, 24, 48 and 96 hours | | Result: | Inhibited glycinamide ribonucleotide formyl transferase (GARFT) activity and GARFT activity was maximally inhibited after at 6 hours.
Decreased the levels of ATP, GTP, dATP, and dGTP of NTDs embryonic brain tissue significantly at 6 hours.
|
| Animal Model: | C57BL/6 mice (7-8 week, 18-20 g)[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal injection; on gestation day 7.5, for 4 days | | Result: | Decreased the expression of proliferation-related genes (Pcna, Foxg1 and Ptch1) and increased the expression of apoptosis-related genes (Bax, Casp8 and Casp9) in NTD groups. |
|
m.cnreagent.com